SAPIEN 3 Transcatheter Pulmonary Valve System with Alterra C Adaptive Prestent
Edwards Lifesciences, LLC · Decision date Oct 27, 2026
What did the FDA approve?
On 2026-10-27, FDA recorded an approval decision (APPR) for P200015/S077, a PMA supplement submitted on the Normal 180 Day Track by Edwards Lifesciences, LLC. The supplement covers the SAPIEN 3 Transcatheter Pulmonary Valve System with Alterra C Adaptive Prestent, a percutaneously delivered pulmonary valve prosthesis under product code NPV in the Cardiovascular specialty.
The recorded scope is a design change to the outflow apices of the Alterra prestent, filed under Change Design/Components/Specifications/Material. This decision modifies that component within the existing P200015 approval rather than constituting a new approval of the whole valve system. The source record includes no documents, so the specific design details, any supporting test data and the review basis are not available here; clinical implications of the apex modification remain unstated.
FDA approval order statement
Approval for a design modification to the outflow apices of the Alterra prestent.
- Regulatory pathway
- PMA supplement
- Supplement type
- Normal 180 Day Track
- Clinical specialty
- Cardiovascular
- Decision date
- Oct 27, 2026
- FDA change category
- Change Design/Components/Specifications/Material
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P200015/S077
- Regulatory pathway
- PMA supplement
- Applicant
- Edwards Lifesciences, LLC
- Product code
- NPV
- Decision code
- APPR
- Decision date
- Oct 27, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Pulmonary valve prosthesis percutaneously delivered.
- Applicant
- Edwards Lifesciences, LLC
- Product code
- NPV
- FDA device class
- f
For the original device and its historical approval scope, see PMA P200015. Subsequent supplements may change the device or its indications.
FDA decision timeline
P200015 · Original PMA
Edwards SAPIEN 3 Transcatheter Heart Valve System with Edwards Commander Delivery System
P200015/S077 received
Application receipt date recorded by FDA.
P200015/S083 · Related supplement
Edwards Crimper (9600LDS20, 9600LDS23, 9600LDS26, 9600LDS29)
P200015/S077 · FDA decision
Normal 180 Day Track
P200015/S084 · Related supplement
Edwards SAPIEN 3 Transcatheter Heart Valve (9600TFX)
Timeline entries are records held by MedtechLedger for P200015. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P200015
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Edwards Lifesciences, LLC | PMA approval | Aug 31, 2020 | FDA | |
| Edwards Lifesciences, LLC | PMA supplement | Sep 23, 2026 | FDA | |
| Edwards Lifesciences, LLC | PMA supplement | Oct 28, 2026 | FDA |
Explore the linked device profile
Other records with product code NPV
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Harmony TPV SystemP200046/S052 | Medtronic, Inc. | PMA supplement | Sep 30, 2026 | FDA |
Harmony TPV SystemP200046 | Medtronic, Inc. | PMA approval | Mar 26, 2021 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Edwards Lifesciences, LLC
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- One Edwards Way, Irvine, CA, 92614
Sources and methodology
- Original FDA record: P200015/S077
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


